Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based start-up that is researching a therapy to combat multiple sclerosis (MS). This therapy has the potential to delay the progression of the
Tags :Vischer
Dermavant Sciences, a clinically focused biopharmaceutical company dedicated to developing and commercializing innovative therapies in the field of immune dermatology, has signed a $160 million revenue interest purchase and sale agreement with three participants for its
Swiss Nuclides, a developer of novel radionuclide Pet tracers for the precision diagnostics, has closed the first tranche of its series A financing round, raising CHF 2.6 million from private investors. Vischer has been acting as
Ubitec, a developer of software solutions for digitization, was taken over by Swiss IT services provider Umb Solution. Umb is strengthening its range of services for the digitization of applications and processes by adding ubitec’
Faveeo, a Swiss start-up operating an AI-driven trusted content platform, announced the successful closing of its Series B financing round. The investment was led by a private equity fund and various business angels. No financial
DomoSafety, a company in the digital health segment developing solutions in the field of patient safety, announced the successful closing of its Series B financing round. The investment was led by Hirslanden, a Swiss healthcare
Vischer acted as legal counsel for Haya Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), on the closing of its CHF 18 million seed round. The financing was led
Oculis has closed an oversubscribed USD 57m Series C financing round. It was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay
Relief Therapeutics Holding and APR Applied Pharma Research have signed a binding term sheet for relief to acquire all outstanding shares of APR. According to the Term Sheet, the APR shareholders will receive from Relief
Drägerwerk AG & Co. KGaA, an international operator in the fields of medical and safety technology, has acquired a majority stake in the Swiss-based start-up medical technology company STIMIT. VISCHER advised Stimit and the
